Diagnostic Center | September 05, 2024
AVEO Oncology announces acceptance of late-breaking oral presentation of TiNivo-2 results at ESMO 2024
Phase 3 clinical trial designed to evaluate the safety and efficacy of tivozanib in combination with nivolumab